28089587|t|Development of (111) In -labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma
28089587|a|Insulinoma is a tumor derived from pancreatic β-cells, and the resulting hyperinsulinemia leads to characteristic hypoglycemia. Recent studies have reported the frequent overexpression of glucagon-like peptide-1 receptor (GLP-1R) in human insulinomas, suggesting that the binding of a radiolabeled compound to GLP-1R is useful for the imaging of such tumors. Exendin(9-39), a fragment peptide of exendin-3 and -4, binds GLP-1R with high affinity and acts as an antagonist. Accordingly, radiolabeled exendin(9-39) derivatives have also been investigated as insulinoma imaging probes that might be less likely to induce hypoglycemia. In this study, we synthesized a novel indium-111 ((111)In)-benzyl-diethylenetriaminepentaacetic acid ((111)In-BnDTPA) -conjugated exendin(9-39), (111)In-BnDTPA-exendin(9-39), and evaluated its utility as a probe for the SPECT imaging of insulinoma. natIn-BnDTPA-exendin(9-39) exhibited a high affinity for GLP-1R (IC50=2.5nM), stability in plasma, and a specific activity that improved following reactions with a solvent and solubilizer. Regarding the in vivo biodistribution of (111)In-BnDTPA-exendin(9-39) in INS-1 tumor -bearing mice, high uptake levels were observed in tumors (14.6%ID/g at 15min), with corresponding high tumor -to- blood (T/B), tumor -to- muscle (T/M), and tumor -to- pancreas (T/P) ratios (T/B =2.55, T/M =22.7, T/P =2.7 at 1h). The pre-administration of excess nonradioactive exendin(9-39) significantly reduced accumulation in both the tumor and pancreas (76% and 68 % inhibition, respectively) at 1h after (111)In-BnDTPA-exendin(9-39) injection, indicating that the GLP-1R mediated a majority of (111)In-BnDTPA-exendin(9-39) uptake in the tumor and pancreas. Finally, (111)In-BnDTPA-exendin(9-39) SPECT/CT studies in mice yielded clear images of tumors at 30min post-injection. These results suggest that (111)In-BnDTPA-exendin(9-39) could be a useful SPECT molecular imaging probe for the detection and exact localization of insulinomas.
28089587	0	11	Development	T169	C1527148
28089587	15	23	(111) In	T130,T196	C0303403
28089587	21	32	In -labeled	T080	C1708632
28089587	33	46	exendin(9-39)	T116	C0247947
28089587	47	58	derivatives	T130	C0358514
28089587	63	113	single-photon emission computed tomography imaging	T060	C0040399
28089587	117	127	insulinoma	T191	C0021670
28089587	128	138	Insulinoma	T191	C0021670
28089587	144	149	tumor	T191	C0027651
28089587	163	181	pancreatic β-cells	T025	C0030281
28089587	201	217	hyperinsulinemia	T047	C0020459
28089587	242	254	hypoglycemia	T047	C0020615
28089587	298	312	overexpression	T045	C1514559
28089587	316	348	glucagon-like peptide-1 receptor	T192	C0378073
28089587	350	356	GLP-1R	T192	C0378073
28089587	361	366	human	T016	C0086418
28089587	367	378	insulinomas	T191	C0021670
28089587	400	407	binding	T044	C1167622
28089587	413	434	radiolabeled compound	T130	C0358514
28089587	438	444	GLP-1R	T192	C0378073
28089587	463	470	imaging	T060	C0011923
28089587	479	485	tumors	T191	C0027651
28089587	487	500	Exendin(9-39)	T116	C0247947
28089587	504	520	fragment peptide	T116	C0030935
28089587	524	533	exendin-3	T116	C0082517
28089587	538	540	-4	T116,T121	C0167117
28089587	542	547	binds	T044	C1167622
28089587	548	554	GLP-1R	T192	C0378073
28089587	565	573	affinity	T070	C1510827
28089587	589	599	antagonist	T121	C0021643
28089587	614	652	radiolabeled exendin(9-39) derivatives	T130	C0358514
28089587	684	694	insulinoma	T191	C0021670
28089587	695	709	imaging probes	T130	C0026381
28089587	746	758	hypoglycemia	T047	C0020615
28089587	768	773	study	T077	C1706256
28089587	778	789	synthesized	T052	C1883254
28089587	798	877	indium-111 ((111)In)-benzyl-diethylenetriaminepentaacetic acid ((111)In-BnDTPA)	T109,T130	C0361442
28089587	890	903	exendin(9-39)	T116	C0247947
28089587	905	933	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	966	971	probe	T130	C0026381
28089587	980	993	SPECT imaging	T060	C0040399
28089587	997	1007	insulinoma	T191	C0021670
28089587	1009	1035	natIn-BnDTPA-exendin(9-39)	T130	C0358514
28089587	1053	1061	affinity	T070	C1510827
28089587	1066	1072	GLP-1R	T192	C0378073
28089587	1087	1096	stability	T080	C0205360
28089587	1100	1106	plasma	T031	C0032105
28089587	1123	1131	activity	T052	C0441655
28089587	1156	1165	reactions	T169	C0443286
28089587	1173	1180	solvent	T130	C0037638
28089587	1185	1196	solubilizer	T130	C0034760
28089587	1212	1219	in vivo	T082	C1515655
28089587	1220	1235	biodistribution	T082	C0037775
28089587	1239	1267	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	1271	1276	INS-1	T191	C0021670
28089587	1277	1282	tumor	T191	C0027651
28089587	1277	1296	tumor -bearing mice	T015	C0025929
28089587	1303	1309	uptake	T039	C0243144
28089587	1310	1316	levels	T080	C0441889
28089587	1334	1340	tumors	T191	C0027651
28089587	1387	1392	tumor	T191	C0027651
28089587	1387	1403	tumor -to- blood	T033	C0243095
28089587	1398	1403	blood	T031	C0005767
28089587	1405	1408	T/B	T033	C0243095
28089587	1411	1416	tumor	T191	C0027651
28089587	1411	1428	tumor -to- muscle	T033	C0243095
28089587	1422	1428	muscle	T024	C0026845
28089587	1430	1433	T/M	T033	C0243095
28089587	1440	1445	tumor	T191	C0027651
28089587	1440	1472	tumor -to- pancreas (T/P) ratios	T033	C0243095
28089587	1451	1459	pancreas	T023	C0030274
28089587	1461	1464	T/P	T033	C0243095
28089587	1474	1477	T/B	T033	C0243095
28089587	1485	1488	T/M	T033	C0243095
28089587	1496	1499	T/P	T033	C0243095
28089587	1517	1535	pre-administration	T061	C1533734
28089587	1546	1574	nonradioactive exendin(9-39)	T116	C0247947
28089587	1589	1596	reduced	T080	C0392756
28089587	1597	1609	accumulation	T033	C4055506
28089587	1622	1627	tumor	T191	C0027651
28089587	1632	1640	pancreas	T023	C0030274
28089587	1653	1665	% inhibition	T081	C1628982
28089587	1693	1721	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	1722	1731	injection	T061	C1533685
28089587	1753	1759	GLP-1R	T192	C0378073
28089587	1783	1811	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	1812	1818	uptake	T039	C0243144
28089587	1826	1831	tumor	T191	C0027651
28089587	1836	1844	pancreas	T023	C0030274
28089587	1855	1883	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	1884	1900	SPECT/CT studies	T060	C3472245
28089587	1904	1908	mice	T015	C0025929
28089587	1933	1939	tumors	T191	C0027651
28089587	1949	1963	post-injection	T079	C2362314
28089587	1992	2020	(111)In-BnDTPA-exendin(9-39)	T130	C0358514
28089587	2039	2044	SPECT	T060	C0040399
28089587	2045	2068	molecular imaging probe	T130	C0026381
28089587	2077	2086	detection	T061	C1511790
28089587	2097	2109	localization	T169	C0475264
28089587	2113	2124	insulinomas	T191	C0021670